Asset acquisitions - Ayala Pharmaceuticals - Fair value of assets and liabilities (Details) - USD ($) $ in Thousands	Mar. 25, 2024	Jun. 30, 2024	Dec. 31, 2023
Assets acquired:
Other long-term assets		$ 3,212	$ 100
Total assets acquired		296,215	148,540
Liabilities assumed:
Total liabilities assumed		$ 42,377	$ 28,658
Ayala Purchase Agreement
Asset acquisitions
Common stock issued to Ayala	$ 50,645
Upfront consideration paid to Ayala	20,039
Transaction costs	657
Consideration paid	71,341
Assets acquired:
In-process research and development	73,382
Other long-term assets	2,480
Total assets acquired	75,862
Liabilities assumed:
Accrued expenses	4,521
Total liabilities assumed	4,521
Net assets acquired	$ 71,341